We did not adjust for anti‐osteoporosis medications (ie, bisphosphonates, parathyroid hormone analogs, and receptor activator of NF‐κB [RANK] ligand inhibitors) given the very low prevalence of these medications in our cohort (n = 14, less than 1%). This evidence concerns the gene PTH and osteoporosis.